Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy Cytokinetics (NASDAQ: CYTK) announced NMPA approval of MYQORZO (aficamten) in China for adults with NYHA class II-III obstructive hypertrophic cardiomyopathy to improve exercise capacity and symptoms.The approval triggers a $7.5 million milestone payment from Sanofi and leaves Cytokinetics eligible for up to $142.5 million additional development/commercial milestones plus royalties in the low-to-high teens on Greater China net sales. MYQORZO is currently approved only in China.Regulatory progress noted: a U.S. NDA is under FDA review with a PDUFA date of December 26, 2025, and the EMA CHMP adopted a positive opinion on December 12, 2025, with a European Commission decision expected in Q1 2026.

#CYTK Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

www.stocktitan.net/news/CYTK/cytokinetics-a...

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy Cytokinetics (Nasdaq: CYTK) announced a positive CHMP opinion recommending EU marketing authorization for MYQORZO (aficamten) to treat symptomatic (NYHA II-III) obstructive hypertrophic cardiomyopathy in adults.A final European Commission decision is expected in Q1 2026. The CHMP opinion cites clinical evidence from the SEQUOIA-HCM trial. Aficamten is also under review by the FDA with a PDUFA date of Dec 26, 2025 and under Priority Review by China’s NMPA CDE.

#CYTK Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

www.stocktitan.net/news/CYTK/cytokinetics-a...

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy Cytokinetics (Nasdaq: CYTK) announced on November 17, 2025 its support for a three-year American Heart Association initiative to improve diagnosis, access, and treatment for people living with hypertrophic cardiomyopathy (HCM).The company said it will back efforts to expand participation in a national HCM Registry powered by Get With The Guidelines®, broaden certification for referring centers, introduce patient support services at key HCM centers, and pilot the Association’s HCM detection algorithm to reduce underdiagnosis.The initiative targets systemic barriers to more consistent, equitable care for the estimated one in 500 U.S. people living with HCM.

#CYTK Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

www.stocktitan.net/news/CYTK/cytokinetics-s...

Cytokinetics Investors Urged to Act Ahead of Class Action Lawsuit Deadline Cytokinetics shareholders are reminded of the lead plaintiff deadline for a pending class action lawsuit. Register by November 17, 2025.

Cytokinetics Investors Urged to Act Ahead of Class Action Lawsuit Deadline #USA #New_York #Gross_Law_Firm #Cytokinetics #CYTK

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track Ex-U.S. Regulatory Reviews of Aficamten Ongoing in China and E.U. ~$1.25 Billion in Cash, Cash Equivalents and Investments as of September 30, 2025 SOUTH SAN FRANCISCO,

#CYTK Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CYTK/cytokinetics-r...

Cytokinetics Shareholders Now Have the Chance to Lead Class Action for Investment Losses Cytokinetics investors who have lost money can step up to lead a class-action securities fraud lawsuit, with a deadline approaching soon.

Cytokinetics Shareholders Now Have the Chance to Lead Class Action for Investment Losses #USA #Los_Angeles #ClassAction #Cytokinetics #CYTK

Levi & Korsinsky Alerts Cytokinetics Investors About a Class Action Lawsuit and Lead Plaintiff Deadline Investors in Cytokinetics, Incorporated have a significant deadline approaching for a class action lawsuit. Ensure your voice is heard by participating before November 17, 2025.

Levi & Korsinsky Alerts Cytokinetics Investors About a Class Action Lawsuit and Lead Plaintiff Deadline #United_States #New_York #Lead_Plaintiff #Cytokinetics #CYTK

Important Deadline Approaches for Class Action Against Cytokinetics: Shareholders Should Act Now Attention Cytokinetics shareholders: There's a critical deadline of November 17, 2025, for joining a class action lawsuit led by The Gross Law Firm. Don't miss this opportunity for recovery.

Important Deadline Approaches for Class Action Against Cytokinetics: Shareholders Should Act Now #United_States #New_York #The_Gross_Law_Firm #Cytokinetics #CYTK

Cytokinetics Faces Legal Action for Alleged Securities Law Breaches Amidst Stock Fluctuations Cytokinetics is under legal scrutiny for alleged securities law violations. Investors impacted by misleading statements should respond before the approaching deadline.

Cytokinetics Faces Legal Action for Alleged Securities Law Breaches Amidst Stock Fluctuations #USA #New_York #The_Gross_Law_Firm #Cytokinetics #CYTK

Cytokinetics Investors Alerted to Class Action Lawsuit for Securities Fraud Cytokinetics investors are urged to join a class action lawsuit for securities fraud affecting shares from December 2023 to May 2025, with a deadline of November 17, 2025.

Cytokinetics Investors Alerted to Class Action Lawsuit for Securities Fraud #USA #New_York #Class_Action #Cytokinetics #CYTK

Cytokinetics Shareholders Urged to Join Class Action Lawsuit by The Gross Law Firm The Gross Law Firm announces a class action for Cytokinetics shareholders, highlighting key deadlines and the process for participation in the lawsuit.

Cytokinetics Shareholders Urged to Join Class Action Lawsuit by The Gross Law Firm #USA #New_York #Gross_Law_Firm #Cytokinetics #CYTK

Cytokinetics Faces Class Action Lawsuit Over Securities Law Violations Investors in Cytokinetics are reminded of a class action lawsuit for securities law violations. Shareholders are encouraged to join for potential recovery.

Cytokinetics Faces Class Action Lawsuit Over Securities Law Violations #United_States #Los_Angeles #DJS_Law_Group #Cytokinetics #CYTK

Class Action Lawsuit Against Cytokinetics: Seeking Recovery for Shareholders The Gross Law Firm has filed a class action lawsuit against Cytokinetics, Incorporated, urging shareholders to take action for potential losses incurred. The case involves misleading statements related to drug application approvals.

Class Action Lawsuit Against Cytokinetics: Seeking Recovery for Shareholders #United_States #New_York #Class_Action #Cytokinetics #CYTK

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025 Cytokinetics (NASDAQ:CYTK) presented new data for aficamten at the HFSA Annual Scientific Meeting 2025, showcasing positive results from two studies. The MAPLE-HCM study demonstrated aficamten's superiority over metoprolol in improving exercise capacity, with significant enhancements in both maximal and submaximal exercise performance.The FOREST-HCM 96-week analysis in non-obstructive HCM patients showed promising long-term efficacy and tolerability. Key findings include 79% of patients improving by at least one NYHA Functional Class, with 74% becoming asymptomatic. The study reported sustained reductions in symptom burden and improvements in cardiac biomarkers, with 82.4% of patients achieving the highest available doses of 15-20 mg.

#CYTK Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

www.stocktitan.net/news/CYTK/cytokinetics-p...

Investors Take Note: Class Action Lawsuit Filed Against Cytokinetics Over Major Losses Pomerantz LLP has initiated a class action lawsuit against Cytokinetics, urging investors who suffered losses to come forward before the deadlines close.

Investors Take Note: Class Action Lawsuit Filed Against Cytokinetics Over Major Losses #USA #New_York #Pomerantz_LLP #Cytokinetics #CYTK

Cytokinetics Shareholders Urged to Join Class Action for Recovery of Losses Cytokinetics, Incorporated shareholders who suffered losses are encouraged to join a class action suit. The Gross Law Firm seeks recovery on behalf of affected investors.

Cytokinetics Shareholders Urged to Join Class Action for Recovery of Losses #United_States #New_York #Gross_Law_Firm #Cytokinetics #CYTK

Cytokinetics Faces Securities Class Action Lawsuit Amid Regulatory Concerns Investors in Cytokinetics, Inc. are urged to join a class action lawsuit regarding past securities fraud allegations before November 17, 2025.

Cytokinetics Faces Securities Class Action Lawsuit Amid Regulatory Concerns #USA #New_York #Securities_Fraud #Cytokinetics #CYTK

Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes Cytokinetics (NASDAQ:CYTK) has priced an upsized $650.0 million convertible senior notes offering due 2031, increased from the initially announced $550.0 million. The notes will carry a 1.75% interest rate and an initial conversion price of $68.42 per share, representing a 37.5% premium over the last reported share price of $49.76.The company will use approximately $402.5 million of the proceeds to refinance existing 3.50% 2027 notes, exchanging approximately $399.5 million of the 2027 notes and issuing 2,168,806 shares of common stock in private transactions. The remaining proceeds will support the potential commercial launch of aficamten and general corporate purposes.The notes will mature on October 1, 2031, with interest payable semi-annually. Cytokinetics granted the initial purchasers an option to purchase an additional $100.0 million in notes within 13 days of the initial issuance.

#CYTK Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes

www.stocktitan.net/news/CYTK/cytokinetics-a...

Breaking News: ( NASDAQ: #CYTK ) CYTK Price Target Alert: $96.00. Issued by Stifel Nicolaus

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025 Cytokinetics (NASDAQ:CYTK) presented new data for aficamten at ESC Congress 2025, strengthening its position as a potential treatment for obstructive hypertrophic cardiomyopathy (oHCM). Key findings from the MAPLE-HCM study showed aficamten's superiority over metoprolol in improving cardiac structure and function.The data revealed that aficamten demonstrated a low annual incidence rate of atrial fibrillation at 1.5%, consistent with expected rates in HCM patients. Long-term safety data from FOREST-HCM showed sustained benefits across 352 patient-years of exposure, with significant improvements in cardiac function and patient symptoms. Notably, 93% of patients reported improvement in NYHA Functional Class at Week 96.Aficamten is currently under FDA review with a PDUFA date of December 26, 2025.

#CYTK Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

www.stocktitan.net/news/CYTK/cytokinetics-p...

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine Cytokinetics (NASDAQ:CYTK) announced positive Phase 3 results from MAPLE-HCM trial, comparing aficamten to metoprolol in patients with obstructive hypertrophic cardiomyopathy (oHCM). The study demonstrated aficamten's superiority over metoprolol across key metrics.The trial's primary endpoint showed significant improvement in exercise capacity with aficamten (+1.1 mL/kg/min) compared to metoprolol (-1.2 mL/kg/min), with a difference of 2.3 mL/kg/min (p. Notably, 51% of aficamten patients showed improved functional class versus 26% for metoprolol.Aficamten demonstrated superiority in five of six secondary endpoints, including significant improvements in cardiac biomarkers and patient symptoms. The drug is currently under FDA review with a PDUFA date of December 26, 2025.

#CYTK Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

www.stocktitan.net/news/CYTK/cytokinetics-a...

Major HCM Drug Trial Results: Cytokinetics' Aficamten vs Metoprolol Data Coming at ESC Congress 2025 Biotech firm to present MAPLE-HCM trial results comparing aficamten to metoprolol, plus atrial fibrillation data from three clinical trials in obstructive HCM at ESC Congress in Madrid.

#CYTK Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025

www.stocktitan.net/news/CYTK/cytokinetics-a...

Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update Cytokinetics (NASDAQ:CYTK) reported Q2 2025 financial results and key business updates. The company ended Q2 with ~$1.0 billion in cash and reported a net loss of $134.4 million ($1.12 per share). Total revenues reached $66.8 million, including $52.4 million from the Bayer collaboration agreement.Key developments include progressing regulatory reviews of aficamten for obstructive HCM, with an FDA PDUFA date of December 26, 2025. The company announced positive topline results from MAPLE-HCM trial and continues advancing multiple Phase 3 clinical trials. Commercial preparations are underway for potential aficamten launch in early 2026.The company maintained its 2025 guidance with GAAP operating expenses projected between $670-710 million.

#CYTK Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CYTK/cytokinetics-r...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#OPEN, #OMI, #SBET, #ACHR, #CYTK

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#OPEN, #OMI, #CYTK, #UMAC, #ONDS

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #OPEN 50% OTM
2. #OMI 39% OTM
3. #CYTK 26% OTM
4. #UMAC 25% OTM
5. #ONDS 23% OTM

#OptionFlow #OptionsTrading #Trading

Major Clinical Trial Results: Cytokinetics Reveals New Aficamten Data vs Metoprolol in HCM Treatment Latest clinical trial data compares Aficamten to Metoprolol in HCM treatment, featuring new safety findings and long-term efficacy results. See full analysis.

#CYTK Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025

www.stocktitan.net/news/CYTK/cytokinetics-a...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CYTK, #HCAT, #WGS, #FTRE, #DAR

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #BA 4.1x
2. #ORCL 4.1x
3. #CYTK 3.5x
4. #GME 3.0x
5. #HCAT 2.2x

#OptionFlow #OptionsTrading #Trading